Clinicians should avoid using the imaging agents regadenoson (Lexiscan, Astellas Pharma US) and adenosine (Adenoscan, Astellas Pharma US) for cardiac nuclear stress tests of patients with signs or ...

Lexiscan Clinical Trials In two identically designed Phase III clinical trials, Lexiscan met primary endpoints for scan agreement rates by showing with 95 percent confidence that MPI studies conducted ...

The U.S. Food and Drug Administration has issued a warning that there is a rare but serious risk of heart attack or death associated with the use of cardiac nuclear stress test agents Lexiscan ...

DEERFIELD, Ill., June 24 Astellas Pharma US, Inc. todayannounced the commercial availability of Lexiscan(TM) (regadenoson) injection,an A2A adenosine receptor agonist, for use as a pharmacologic ...

WASHINGTON, Nov. 20 (UPI) -- The U.S. Food and Drug Administration warns doctors of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents. The cardiac ...

HealthDay News — The FDA is warning healthcare providers about a rare, but serious, risk for heart attack and death with use of two cardiac nuclear stress test agents — regadenoson (Lexiscan) and ...

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. May 13, ...

The drug regadenoson is safe and poses fewer side effects than the conventional medication used during a cardiac nuclear stress test of heart transplant patients, according to a Henry Ford Hospital ...

Lexiscan is the first A2A adenosine receptor agonist shown to be safe and effective as a pharmacologic stress agent in MPI studies. Lexiscan is delivered as a rapid bolus (approximately 10 seconds) ...

PALO ALTO, Calif. and DEERFIELD, Ill., April 10 -- CV Therapeutics and Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lexiscan(TM) (regadenoson) ...